Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624 1631 1641 1677 1678
This examiner grants 32% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18317772 | METHODS OF TREATING METACHROMATIC LEUKODYSTROPHY | Non-Final OA | Genzyme Corporation |
| 18143902 | VARIANT ADENO-ASSOCIATED VIRUS (AAV) CAPSID POLYPEPTIDES AND GENE THERAPEUTICS THEREOF FOR TREATMENT OF HEARING LOSS | Non-Final OA | Eli Lilly and Company |
| 16487517 | METHODS OF PHOTOCHEMICAL TREATMENT FOR WOUND HEALING | Non-Final OA | The General Hospital Corporation |
| 17919052 | ENHANCED EFFECTS OF GENE-IMMUNOTHERAPY AND IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 17907510 | GENOME ENGINEERING USING CRISPR RNA-GUIDED INTEGRASES | Final Rejection | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18296895 | Protein Tyrosine Phosphatase 1B Inhibited Neutrophils, Neutrophil-Dendritic Cell Hybrids and Uses Thereof | Non-Final OA | WISCONSIN ALUMNI RESEARCH FOUNDATION |
| 18257534 | Chemically Defined Serum Albumin Substitutes | Non-Final OA | Life Technologies Corporation |
| 18298882 | COMBINATION TREATMENT | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18279936 | METHODS FOR IMPROVING EARLY EMBRYO DEVELOPMENT | Non-Final OA | SHANDONG UNIVERSITY |
| 18568061 | EXOSOME PRODUCTION PROMOTING AGENT AND EXOSOME PRODUCTION PROMOTING METHOD | Non-Final OA | FULLSTEM CO., LTD. |
| 18285829 | ADENO-ASSOCIATED VIRUS VIRION FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | Non-Final OA | GENE THERAPY RESEARCH INSTITUTION CO., LTD. |
| 18554136 | Pancreatic Islets as Protein Factories | Non-Final OA | BIOCRINE AB |
| 18277394 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3 GENES | Non-Final OA | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
| 18276593 | RECONSTITUTION OF EXTRACELLULAR MATRIXES FOR MUSCULOSKELETAL JOINT TISSUE REPAIR USING BIOMIMETIC BIOLOGIC AND SYNTHETIC FACTORS | Non-Final OA | Rhode Island Hospital |
| 18260406 | GENETICALLY-MODIFIED PLURIPOTENT STEM CELLS AND DERIVED NATURAL KILLER CELLS AND METHODS FOR PRODUCING THE SAME | Non-Final OA | NUWACELL BIOTECHNOLOGIES CO., LTD. |
| 18269270 | Method for Producing Naive Human IPS Cells From Somatic Cells | Final Rejection | ID PHARMA CO., LTD. |
| 18001462 | 3D CULTURE OF MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS | Final Rejection | MESOBLAST INTERNATIONAL SÁRL |
| 18092495 | MAMMALIAN LIVESTOCK PLURIPOTENT STEM CELLS FROM DELAYED EMBRYOS | Final Rejection | Accellta Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy